A GCO trial exploring the efficacy and safety of Nivolumab monotherapy or Nivolumab plus Ipilimumab in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs)

Avis favorable du Comité de Protection des Personnes : 03/04/2018

Autorisation de l'ANSM : 15/03/2018

Premier centre ouvert : 13/10/2018

Premier patient inclus : 02/01/2019

N° Eudract : 2017-003863-37

Lien Clinicaltrials.gov : NCT03591731

Download attachments:
Read 2190 times Last modified on Friday, 01 February 2019 19:18